Daily Respiratory Research Analysis
Analyzed 45 papers and selected 3 impactful papers.
Summary
Analyzed 45 papers and selected 3 impactful articles.
Selected Articles
1. Targeting macrophage ferritin heavy chain mitigates ferroptosis and lung injury in experimental acute respiratory distress syndrome.
Human ARDS samples and a hyperoxia lung-injury model revealed enrichment of ferritin subunits (FTH1/FTL) in serum and myeloid compartments. Myeloid targeting of FTH1 reduced ferroptosis and attenuated lung injury, positioning macrophage-derived ferritin as a mechanistic driver and therapeutic target in ARDS.
Impact: Defines a novel macrophage iron-handling mechanism driving ferroptosis in ARDS and demonstrates targetability of FTH1 with therapeutic effect in vivo.
Clinical Implications: Serum/extracellular ferritin signatures may aid risk stratification in ARDS, and FTH1/ferroptosis-directed therapies (e.g., anti-ferroptotics or macrophage-targeted strategies) warrant translational development.
Key Findings
- FTH1 and FTL were enriched in serum, blood monocytes, and alveolar macrophages from patients with ARDS and in a murine hyperoxia model.
- Myeloid-specific manipulation of FTH1 mitigated ferroptosis and reduced acute lung injury severity.
- Data implicate macrophage-derived extracellular ferritin as a mechanistic contributor to ARDS pathobiology and a viable therapeutic target.
Methodological Strengths
- Integration of human ARDS biospecimens with mechanistic mouse models
- Cell lineage-specific genetic targeting to establish causality for FTH1
Limitations
- Preclinical model (hyperoxia-induced lung injury) may not capture all ARDS etiologies
- Human cohort size and interventional validation details are limited in the abstract
Future Directions: Validate ferritin-based biomarkers in diverse ARDS phenotypes; develop and test macrophage-targeted FTH1/ferroptosis inhibitors in translational and early-phase clinical studies.
Ferritin, composed of heavy chain (FTH1) and light chain (FTL) subunits, is a key intracellular iron storage protein, but the origin and biological role of extracellular ferritin (ex-ferritin) remain poorly understood. Elevated serum ex-ferritin is associated with worse outcomes in acute respiratory distress syndrome (ARDS). Here, we show that both FTH1 and FTL are significantly enriched in the serum, blood monocytes, and alveolar macrophages (AM) of individuals with ARDS, findings we replicate in a murine hyperoxia-induced acute lung injury model. Myeloid-specific FTH1 (Fth1
2. Systemic atopy and upper-airway disease define susceptibility to incident asthma after COVID-19 in Korea.
In a nationwide propensity-matched cohort of nearly 4 million SARS-CoV-2–infected individuals, pre-existing systemic atopy and upper-airway disease conferred a 66% higher hazard of incident asthma post-COVID-19, with risk increasing alongside multimorbidity burden.
Impact: Provides population-scale risk stratification for post-COVID asthma using real-world data, directly informing surveillance and preventive strategies.
Clinical Implications: Prioritize post-COVID asthma surveillance and early management for patients with allergic rhinitis, chronic rhinosinusitis, atopic dermatitis, or food allergy; counsel high-risk groups and consider timely spirometry and preventive therapy.
Key Findings
- In 1:1 propensity-matched analyses, pre-existing systemic atopy/upper-airway disease was associated with higher incident asthma after COVID-19 (HR 1.66, 95% CI 1.58–1.75).
- Asthma incidence increased with greater allergic disease burden, and each individual condition conferred elevated risk.
- Findings support targeted post-COVID surveillance in allergic and upper-airway disease subgroups at the national level.
Methodological Strengths
- Nationwide, large-scale cohort with propensity score matching
- Consistent effect across multiple allergic phenotypes and multimorbidity gradients
Limitations
- Claims-based asthma definitions may misclassify disease
- Residual confounding and limited generalizability beyond Korean population
Future Directions: Validate risk algorithms incorporating atopy/upper-airway phenotypes in diverse populations; assess preventive interventions (e.g., anti-inflammatory therapy) post-COVID among high-risk groups.
Incident asthma is an important respiratory sequela after COVID-19, but it is unclear which allergic phenotypes amplify risk. Using a linked nationwide Korean database of 3,987,182 individuals with confirmed severe acute respiratory syndrome coronavirus 2 infection, we compare claims-based incident asthma in those with pre-existing systemic atopy and/or upper-airway disease (allergic rhinitis, chronic rhinosinusitis, atopic dermatitis or food allergy) versus those without after 1:1 propensity score matching. During follow-up to 31 December 2022, participants with pre-existing disease have higher asthma incidence than matched controls (3.55 vs 2.13 per 1,000 person-years), with a hazard ratio of 1.66 (95% confidence interval 1.58-1.75). Asthma risk is elevated for each condition and increases with greater disease burden. These findings show that pre-existing allergic and upper-airway phenotypes stratify post-COVID incident asthma risk on a national scale, supporting targeted surveillance in high-risk subgroups.
3. IL-11 neutralizing antibodies alleviate pulmonary fibrosis in aging mice by inhibiting TGF-β/NOX4/IL-11 signaling pathway.
IL-11 was upregulated in serum, lungs, and fibroblasts of aging fibrotic mice; IL-11 overexpression promoted, while loss-of-function attenuated, senescent fibroblast profibrotic phenotypes. Neutralizing IL-11 antibodies reduced both early and late fibrosis via TGF-β1/NOX4/IL-11 signaling, supporting IL-11 as a therapeutic anti-fibrotic target.
Impact: Links aging biology to fibrotic signaling and demonstrates antibody-based reversal of fibrosis in vivo, opening a translational path for IPF where options are limited.
Clinical Implications: IL-11 pathway inhibitors could complement existing anti-fibrotics for elderly IPF; biomarker-driven selection (e.g., IL-11/NOX4 activity) and timing (early vs late disease) may be critical.
Key Findings
- IL-11 expression was elevated in serum, lung tissue, and fibroblasts of aging fibrotic mice.
- IL-11 neutralizing antibodies alleviated pulmonary fibrosis in vitro and in vivo, effective in both early and late disease settings.
- Mechanistic studies implicated the TGF-β1/NOX4/IL-11 axis in regulating senescent lung fibroblast profibrotic phenotypes.
Methodological Strengths
- Combined in vitro and in vivo validation including aging mouse models
- Mechanistic dissection of TGF-β1/NOX4/IL-11 signaling with functional perturbations
Limitations
- Preclinical findings require human validation and safety profiling
- Antibody efficacy and pharmacokinetics in aged human lung tissue remain unknown
Future Directions: Translate IL-11 blockade to early-phase clinical trials in IPF with enrichment for aging biology; develop companion biomarkers (IL-11/NOX4) and explore combination with approved anti-fibrotics.
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive fibrotic interstitial lung disease mainly occurs in the elderly, presents limited therapeutic options and necessitating the development of novel drugs. Interleukin-11 (IL-11) belongs to the interleukin-6 (IL-6) family and plays a wide role in fields such as hematopoiesis, immune regulation and tumorigenesis. Recent studies have shown that IL-11 could serve as a potential target for the treatment of IPF and plays a certain role in the aging process. In this study we aims to evaluate the role and mechanism of targeted IL-11 in aging-related pulmonary fibrosis. Firstly, neutralizing antibodies targeting IL-11 were obtained through evaluation and combination of two antibodies with different epitopes can effectively alleviate pulmonary fibrosis in vivo and in vitro. Subsequently, we established pulmonary fibrosis model in aging mice and found that IL-11 was highly expressed in the serum, lung tissues and fibroblasts of fibrotic aging mice. The overexpression or functional loss of IL-11 could significantly change the profibrotic phenotype of senescent lung fibroblasts, and IL-11 neutralizing antibodies could effectively alleviate early and late pulmonary fibrosis in aging mice. Further mechanism studies have confirmed the importance of the TGF-β1/NOX4/IL-11 signaling pathway in regulating the senescence phenotype of lung fibroblasts and aging-related pulmonary fibrosis. In summary, this study elucidate the correlation between IL and 11 and pulmonary fibrosis in aging mice. Both in vitro and in vivo experiments have validated the therapeutic efficacy and molecular mechanisms of IL-11-neutralizing antibodies in pulmonary fibrosis, offering promising insights for future anti-fibrotic drug development. Abbreviations: IL-11, Interleukin-11; IPF, Idiopathic pulmonary fibrosis; TGF-β, Transforming growth factor-β; NOX4, NADPH oxidase-4; SASP, Senescence-associated secretory phenotype; ECM, Extracellular matrix; α-SMA, α-smooth muscle actin; STAT3, Signal transducer and activator of transcription 3; ERK, Extracellular regulated protein kinases; AKT, Protein kinase B; BLM, Bleomycin; WT, Wild-type; KO, Knockout; qRT-PCR, Quantitative real-time polymerase chain reaction; WB, Western blot; hAb, Humanized antibody; mAb, Monoclonal antibody; FVC, Forced vital capacity; CTGF, Connective tissue growth factor; PDGFR-α, Platelet-derived growth factor receptor-α; TNF-α, Tumor necrosis factor-α; Nrf2, NFE2-related factor 2; EMT, Epithelial-mesenchymal transition; HE, Hematoxylin and eosin; PVDF, Polyvinylidene fluoride; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; siRNA, Small interfering RNA; IL-6, Interleukin-6; MEK, Mitogen-Activated Protein Kinase Kinase; TIME, TGF-β1/IL-11/MEK/ERK; HRP, Horseradish Peroxidase; MLG, Mouse lung fibroblast cell line MLg; NCBI, National Center for Biotechnology Information; Bcl2, BCL2 apoptosis regulator; Bax, BCL2 Associated X, apoptosis regulator; MSC, Mesenchymal Stem Cell; RSK, p90 Ribosomal S6 Kinase; KD, Dissociation Constant; Nin, Nintedanib; CTL, Control; Eto, Etoposide; SA-β-Gal, Senescence-Associated β-Galactosidase.